Following nearly 20 reports of vision problems from Ozempic or Wegovy since a study was published in July 2024, Danish health officials are calling for an EU investigation into the safety of semaglutide-based drugs.
The Bard PowerPort lawsuits will go through additional fact specific discovery over the next few months, before the parties determine which six will serve best as early bellwether trials.
Judge presiding over all federal hair relaxer lawsuits has ordered the parties to submit separate briefing on the bellwether selection process by January 3.